Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation

Author's Avatar
Jan 28, 2021
Article's Main Image
  • FIRST DOSE OF EVT894, A MONOCLONAL ANTIBODY AGAINST CHIKUNGUNYA VIRUS ADMINISTERED TO A HEALTHY PARTICIPANT IN A PHASE I STUDY
  • DEVELOPMENT OF EVT894 BY EVOTEC TOGETHER WITH ITS PARTNERS NIAID AND DUKE CLINICAL RESEARCH INSTITUTE
  • ADDRESSING UNMET MEDICAL NEEDS IN GLOBAL HEALTH